The HIV positivity rate among pregnant women attending prenatal consultations is 0.1% in 2025.
Updated data: The first national HIV and hepatitis B prevalence survey among pregnant women, which will be conducted by the Ministry of Health with the involvement of WHO and the UNAIDS office, will provide up-to-date data on the prevalence of these two viruses and guide strategic interventions.
The Ministry of Health and Social Protection will carry out the first national HIV and hepatitis B prevalence survey among pregnant women in Morocco. It will be carried out by the ministry with the involvement of the WHO and the UNAIDS office and financed as part of the grant from the Global Fund Morocco. The department of epidemiology and disease control through the national AIDS control program (PNLS) has just launched a call for applications to support it in conducting this investigation. This will be carried out among pregnant women attending prenatal consultations in the public and private sectors. This survey will provide up-to-date data on the prevalence of HIV and hepatitis B and guide strategic interventions. Note that this prevalence study is scheduled between May and November 2026.
Morocco is committed to eliminating mother-to-child transmission (eMTCT) of HIV, syphilis and hepatitis B as a national public health priority. This approach aims to guarantee universal access to quality services in reproductive, maternal, neonatal and child health, in order to reduce the transmission of these infections from mother to child and to ensure optimal care for infected pregnant women. The Integrated National Strategic Plan to Combat AIDS, Sexually Transmitted Infections and Viral Hepatitis 2024-2030 targets triple eMTCT by 2030. A national roadmap for eMTCT was updated in 2025 to identify priorities for action to accelerate the achievement of the expected objectives with the involvement of all sectors.
In Morocco, the prevalence of HIV in the general population is estimated at 0.09% in 2025, according to data from the national AIDS 2026 report, and the HIV positivity rate among pregnant women attending prenatal consultations is 0.1% in 2025. That said, the actual prevalence of HIV among pregnant women remains imprecise. As for hepatitis B, the national seroprevalence study of viral hepatitis carried out by the Ministry of Health dates back to 2019 and reported a prevalence of 0.7%. No data is currently available from the ministry regarding the positivity rate or prevalence of hepatitis B in pregnant women. Note that the screening and treatment system for hepatitis B is being implemented by integrating that for HIV and hepatitis C.
